Twist Bioscience (NASDAQ:TWST) Earns Buy Rating from TD Cowen

Twist Bioscience (NASDAQ:TWST)‘s stock had its “buy” rating reiterated by research analysts at TD Cowen in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $58.00 target price on the stock. TD Cowen’s price objective would suggest a potential upside of 20.03% from the stock’s previous close.

Several other research analysts have also recently weighed in on TWST. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $48.32 on Tuesday. Twist Bioscience has a one year low of $23.07 and a one year high of $60.90. The business has a fifty day moving average price of $43.75 and a 200 day moving average price of $46.20. The company has a market cap of $2.87 billion, a P/E ratio of -13.21 and a beta of 1.78.

Insiders Place Their Bets

In related news, insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the sale, the insider now owns 91,163 shares in the company, valued at $4,375,824. This represents a 1.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Chess sold 3,600 shares of Twist Bioscience stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now owns 21,641 shares in the company, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 in the last ninety days. 3.92% of the stock is owned by corporate insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently added to or reduced their stakes in TWST. American International Group Inc. grew its holdings in Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the period. PEAK6 Investments LLC boosted its position in Twist Bioscience by 20.7% during the first quarter. PEAK6 Investments LLC now owns 14,000 shares of the company’s stock worth $480,000 after purchasing an additional 2,400 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Twist Bioscience by 7.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after buying an additional 2,292 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after buying an additional 37,376 shares in the last quarter. Finally, Bayesian Capital Management LP grew its stake in Twist Bioscience by 42.7% in the 1st quarter. Bayesian Capital Management LP now owns 14,546 shares of the company’s stock valued at $499,000 after acquiring an additional 4,352 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.